Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 3 B, 2005, Pages 738-740

  Perez Fiore, Ana Patricia ^a,b   Fragoso, Yara Dadalti ^a,c,d  

^a UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

^b Nursing School UNIMES   (Brazil)

^c Medical School UNIMES   (Brazil)

^d NONE   (Brazil)

Author keywords

Copaxone; Glatiramer acetate; Multiple sclerosis

Indexed keywords

GLATIRAMER;

ADVERSE DRUG REACTION; AIRWAY CONSTRICTION; ANXIETY; BRAZIL; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; FLUSHING; HEART PALPITATION; HUMAN; INJECTION PAIN; INJECTION SITE REACTION; LIPOATROPHY; LONG TERM CARE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRURITUS; REVIEW; SIDE EFFECT; THORAX PAIN; TIME;

EID: 27144481709     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2005000500002     Document Type: Review

References (13)

1. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in multiple sclerosis. CNS Drugs 2002;16:825-850.
2. Francis DA. Glatiramer acetate (Copaxone). Int J Clin Pract 2001;55:394-398.
3. Putheti P, Soderstrom M. Link H, Huang YM. Effects of glatiramer acetate (Copaxone) on CD4+CD25 high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 2003;144:125-131.
4. Dhib-Jabult S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003;98:245-255.
5. Ziemssem T, Neuhaus O, Hothfield R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001;24:979-990.
6. Munari LM, Fillippini G. Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol 2004;3:641.
7. Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58-63.
8. Rothwell PM. External validity of randomized clinical trials: "to whom do the results of this trial apply?" Lancet 2005;365:82-93.
9. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004678.
10. Fletcher S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 2002;197:51-55.
11. Wolinsky JS. Glatiramer acetate for the treatment of multiple sclerosis. Expert Opin Pharmacother 2004;5:875-891.
12. Tilbery CP, Moreira MA, Mendes MF, et al. Recomendações quanto ao uso de drogas imunomoduladoras na esclerose múltipla: o consenso do BCTRIMS. Arq Neuropsiquiatr 2000;58:769-776.
13. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003;170:4483-4488.